Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

204
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
204
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

211
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
211
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

772
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
772
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

208
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
208
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

340
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
340
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An evaluation of the necessity of repeat testing of critical and dangerous values in a medical center in Taiwan.

Laboratory medicine·2026
Same author

A TriNetX global collaborative network retrospective cohort study on the impact of COVID-19 vaccination on juvenile idiopathic arthritis.

Scientific reports·2026
Same author

Authors' reply.

Annals of gastroenterology·2026
Same author

Workflow-embedded automation improves hepatitis B screening and safety in b/tsDMARD users.

BMC infectious diseases·2026
Same author

Massive Hematochezia from a Polypoid Lesion in the Descending Colon.

Digestive diseases and sciences·2026
Same author

Association of SGLT2 inhibitors with hematologic malignancies in type 2 diabetes: a target trial emulation study.

Diabetes research and clinical practice·2026

Related Experiment Video

Updated: Jan 13, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.7K

Colchicine Use in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.

Huey Chiat Cheong1,2, Meng Hsuan Kuo3, Chih-Wei Tseng2,4

  • 1Division of Cardiology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 2, Minsheng Rd., Dalin Township, Chiayi County 62247, Taiwan.

Journal of Clinical Medicine
|January 10, 2026
PubMed
Summary

Colchicine may reduce major adverse cardiovascular events (MACE) in acute coronary syndrome (ACS) patients, but does not improve mortality. Gastrointestinal side effects like diarrhea are common with this anti-inflammatory drug.

Keywords:
acute coronary syndromecolchicineinflammationmajor adverse cardiovascular eventsmeta-analysis

More Related Videos

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

16.6K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K

Related Experiment Videos

Last Updated: Jan 13, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.7K
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

16.6K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Acute coronary syndrome (ACS) poses significant cardiovascular risks.
  • Identifying effective adjunctive therapies for ACS management is crucial.
  • Colchicine, an anti-inflammatory agent, is being investigated for its role in cardiovascular disease.

Purpose of the Study:

  • To systematically review and meta-analyze randomized controlled trials (RCTs) on colchicine in ACS patients.
  • To assess colchicine's efficacy in reducing major adverse cardiovascular events (MACE).
  • To evaluate its impact on inflammatory markers, optimal dosing, timing, and safety.

Main Methods:

  • Comprehensive literature search of PubMed, Embase, and Cochrane Library adhering to PRISMA guidelines.
  • Inclusion of 15 RCTs with 19,131 patients comparing colchicine to placebo or standard care in ACS.
  • Primary outcome: MACE; Secondary outcomes: mortality, MI, stroke, revascularization, heart failure, CRP/hs-CRP, adverse events.

Main Results:

  • Colchicine showed a marginally significant reduction in MACE risk (RR=0.79, p=0.04).
  • No significant benefits were found for all-cause mortality, cardiovascular mortality, or other cardiovascular outcomes.
  • Gastrointestinal side effects, particularly diarrhea (RR=1.76, p=0.001), were the most frequent adverse events.

Conclusions:

  • Colchicine may offer a potential benefit in reducing MACE for ACS patients.
  • Current evidence does not support its use for improving mortality or other cardiovascular outcomes.
  • Gastrointestinal intolerance is a primary concern, necessitating further research for optimal patient selection and treatment regimens.